Biogen and Eisai have resurrected hopes that amyloid-targeting drugs could have a benefit in Alzheimer's disease with a claim that their new drug lecanemab showed a "highly statistically ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

If you buy something, we may earn an affiliate commission. Like so many elite outerwear silhouettes, the best shirt jackets for men are descendants of utilitarian pieces designed for lumberjacks ...

Looking for high-quality and the best men's shirt brands? Read this article to know the price and details of the best shirt brands for men. "There is no fashion for men" is the common phrase every ...

Future of Healthcategory Benefit of Eisai and Biogen's Alzheimer's drug increases over time, studies suggest July 30, 2024 Businesscategory Shares of Japan's Eisai tumble after EU rejects ...

T-Mobile is the third-largest wireless carrier in the United States, with its popularity largely down to its network coverage and the wide range of tempting offers available. They span from T ...

Whether it’s for work or a wedding, nothing makes a man feel smarter than pulling on a crisp shirt, especially when it’s box-fresh and just ironed. But there are so many styles to choose from ...

An icon in the shape of a lightning bolt. Impact Link President Volodymyr Zelenskyy showed up to his evening video address in an unusual T-shirt and got a scathing reaction from the Kremlin.

According to a New York Times report this week, Eisai and Eli Lilly, in the clinical trials for their respective Alzheimer’s drugs Leqembi and Kisunla, genetically tested participants to ...

Baggy suits, baggy pants, baggy T-shirts—they're definitively cool, and it's time to start stocking up. Let your slim-cut T-shirts take a break for a little while, and don't be afraid of what an ...

For the drugmaker Eisai, the trial was a shot at a windfall — potentially billions of dollars — for defanging a disease that had confounded researchers for more than a century. To assess the ...

Japanese drugmaker Eisai has teamed up with UK biotech Wren Therapeutics on an R&D programme seeking drugs for neurodegenerative disorders. The two companies will focus their efforts on alpha ...